| Q33621078 | A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge |
| Q35874598 | A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines |
| Q34064413 | Branched-linear and agglomerate protein polymers as vaccine platforms |
| Q40836583 | Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines |
| Q77051038 | Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain |
| Q35848642 | Effects of adjuvants on IgG subclasses elicited by virus-like particles |
| Q47132009 | Escherichia coli-derived virus-like particles in vaccine development |
| Q35180387 | Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic |
| Q52928643 | Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children. |
| Q36473324 | Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. |
| Q73594344 | Lack of compliance with hepatitis B vaccination among Canadian STD clinic patients: candidates for an accelerated immunization schedule? |
| Q40447718 | Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation. |
| Q38293586 | Old and new adjuvants for hepatitis B vaccines |
| Q37158131 | Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administration. |
| Q51970939 | Prevalence of hepatitis B infection in long-stay mentally handicapped adults. |
| Q38819439 | Recent advancements in combination subunit vaccine development |
| Q44363692 | Simultaneous administration of hepatitis B vaccine with other E.P.I. vaccines |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q37792984 | Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design |
| Q38702017 | Virus-based nanoparticles as platform technologies for modern vaccines |
| Q36602264 | Virus-like particles: passport to immune recognition |